Clinical HBOC Surveillance Tool Inspired by Netflix: Earle Meets World

BRCA2 Hereditary Risk & Screening Interval Planner

Evidence-based NCCN screening cadences and cumulative lifetime probability curves for BRCA2 mutation carriers.

Patient Profile

Current Age: 32

Screening recommendations shift at ages 25, 30, and 35.

Genetic Mutation Status

Family Cancer History

Mother (Breast Cancer < 50) Maternal Aunt (Ovarian Cancer) First-degree Male Breast Cancer Pancreatic or Aggressive Prostate Cancer

Clinical Modifiers

Prior Breast Biopsy (Benign/Atypical) Ashkenazi Jewish Ancestry

Lifetime Breast Cancer Risk

69.5%

By age 80 (Avg pop: ~12.9%)

Lifetime Ovarian Risk

17.0%

By age 80 (Avg pop: ~1.2%)

Surveillance Cadence

Every 6 Mo

Alternating MRI & Mammogram

Personalized Screening Roadmap (Age 32)

Modality	Standard Interval	Status for Current Age	Clinical Notes

Cumulative Probability Trajectory (Ages 25–80)

Breast Cancer Risk

Ovarian Cancer Risk

Population Baseline

Next Clinical Action Steps

Export Clinical Surveillance Checklist

Download a structured physician discussion brief with calculated risk parameters.

Clinical Summary Record

Status: High Risk (HBOC Syndrome - BRCA2 Positive)

Cumulative Breast Risk to Age 80: 69.5%

Cumulative Ovarian Risk to Age 80: 17.0%

Annual Contrast MRI: true

Clinical Exam Cadence: Every 6 months

Mammography Recommended Start: Age 30

Clinical References & Evidence Grounding

Guidelines synthesized from the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic (Version 3.2024 / 2025 Updates), and published peer-reviewed prospective cohort studies (Kuchenbaecker et al., JAMA 2017).

• NCCN Guidelines for Detection, Prevention, & Risk Reduction: Breast & Ovarian Hereditary Syndromes
• Kuchenbaecker KB, et al. Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. JAMA. 2017;317(23):2402-2416.
• American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 182: Hereditary Breast and Ovarian Cancer Syndrome.

Disclaimer: This digital planning workbench is an educational decision-aid tool inspired by public health discussions and high-profile genomic disclosures. It does not constitute formal medical diagnosis or replace personalized counseling by a board-certified genetic counselor or breast surgical oncologist.

Super generates helpful tools and automates fact-checking across the internet proactively. If you enjoyed this tool, build your own with Super and share it with a friend.